Literature DB >> 27765591

Functional and Morphological Outcomes of Pyeloplasty at Different Ages in Prenatally Diagnosed Society of Fetal Urology Grades 3-4 Ureteropelvic Junction Obstruction: Is It Safe to Wait?

Dapeng Jiang1, Bingqiang Tang1, Maosheng Xu1, Houwei Lin1, Longhu Jin1, Lei He1, Guofeng Xu1, Xiaoliang Fang1, Hongquan Geng2.   

Abstract

OBJECTIVE: To evaluate changes in functional and morphological outcomes in children with prenatally diagnosed Society of Fetal Urology (SFU) grades 3-4 ureteropelvic junction obstruction (UPJO) who underwent pyeloplasty at different ages. We also examined the effect of surgical wait time on recovery of renal function.
MATERIALS AND METHODS: All patients (aged 0-12 months) with prenatally diagnosed SFU grades 3-4 UPJO who underwent pyeloplasty in a single center between January 2013 and December 2015 were reviewed. One hundred thirty-three children were enrolled in this study. The children were divided into 2 groups according to their age at the time of surgery (group I: 0-3 months, group II: 3-12 months). We evaluated changes in parenchymal thickness, anteroposterior diameter (APD), and differential renal function (DRF) using ultrasound and diuretic renography. Functional and morphological outcomes were compared using Student t test.
RESULTS: A total of 133 patients were included in the study. We found a significant difference in the change of DRF (difference between before and after pyeloplasty) between the 2 groups (P < .05). There were no significant differences in changes in parenchymal thickness and APD. Patients who waited 1-2 months had a significantly lower functional improvement compared with those who waited less than 1 month.
CONCLUSION: Early surgery leads to a significant improvement in DRF. Wait times greater than 1 month can decrease functional improvement. For patients with prenatally diagnosed SFU grades 3-4 UPJO, early pyeloplasty is recommended in those with increasing renal pelvic APD and an obstructed renogram with differential renal function <40%.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27765591     DOI: 10.1016/j.urology.2016.10.004

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  An initial differential renal function between 35% and 40% has greater probability of leading to normal after pyeloplasty in patients with unilateral pelvic-ureteric junction obstruction.

Authors:  Guofeng Xu; Maosheng Xu; Jianqi Ma; Zhoutong Chen; Dapeng Jiang; Zhihua Hong; Houwei Lin; Xiaoliang Fang; Liguo Wang; Lei He; Hongquan Geng
Journal:  Int Urol Nephrol       Date:  2017-08-09       Impact factor: 2.370

2.  Uretero-Pelvic Junction Stenosis: Considerations on the Appropriate Timing of Correction Based on an Infant Population Treated with a Minimally-Invasive Technique.

Authors:  Mario Lima; Niel Di Salvo; Andrea Portoraro; Michela Maffi; Giovanni Parente; Vincenzo Davide Catania; Tommaso Gargano
Journal:  Children (Basel)       Date:  2021-02-04

3.  Postnatal management of bilateral Grade 3-4 ureteropelvic junction obstruction.

Authors:  Ramesh Babu; Ashay Rajnikant Suryawanshi; Utsav Shailesh Shah; Ashitha K Unny
Journal:  Indian J Urol       Date:  2020-10-01

4.  Urine Biomarkers Combined With Ultrasound for the Diagnosis of Obstruction in Pediatric Hydronephrosis.

Authors:  Vytis Kazlauskas; Vytautas Bilius; Virginijus Jakutis; Renata Komiagiene; Birute Burnyte; Gilvydas Verkauskas
Journal:  Front Pediatr       Date:  2022-01-06       Impact factor: 3.418

5.  Comparison of Drainage Methods After Pyeloplasty in Children: A 14-Year Study.

Authors:  Xiangpan Kong; Zhenpeng Li; Mujie Li; Xing Liu; Dawei He
Journal:  Front Pediatr       Date:  2021-12-13       Impact factor: 3.418

6.  Comparative transcriptome analysis of miRNA in hydronephrosis male children caused by ureteropelvic junction obstruction with or without renal functional injury.

Authors:  Ge Liu; Xin Liu; Yi Yang
Journal:  PeerJ       Date:  2022-02-25       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.